Condition: Prostate Cancer · Prostate Adenocarcinoma · Sponsor: Curium US LLC
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
This description comes directly from the study's public registry record.
Hassan El Gazri · +33 7 69 28 53 40 · SOLAR@curiumpharma.com
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama | Homewood, Alabama, United States | Recruiting |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| Tower Urology | Los Angeles, California, United States | Recruiting |
| VA Greater Los Angeles Healthcare System | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| San Francisco VA Medical Center | San Francisco, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Providence Saint John's Health Center | Santa Monica, California, United States | Completed |
| Stanford Hospital & Clinics | Stanford, California, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Completed |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06235151